Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED

- ETHY-001 produced complete blockade of autoantibody-mediated TSHR activation across all patient serum samples tested, demonstrating breadth and consistency of effect - - In TED patient-derived orbital fibroblasts, ETHY-001 fully suppressed both hyaluronan (HA) and interleukin-6 (IL-6) secretion, offering a differentiated profile compared to IGF-1R antagonism - - ETHY-001 demonstrated sub-nanomolar binding affinity to TSHR with no off-target binding across more than 5,000 human membrane protein